MD Lash Factor® vs Latisse: A Physician's Honest Comparison
By Susan F. Lin, M.D. | Physician | Reviewed: September 2026
A note before you read: This article compares a prescription medication (Latisse®) with a cosmetic eyelash conditioner for educational purposes only. Latisse® is prescribed and monitored by a physician — never start, stop, or change a prescription because of an article; talk with your prescribing physician or eye-care professional. MD Lash Factor® is a cosmetic conditioner and is not intended to diagnose, treat, cure, or prevent any disease.
Quick Answer
Latisse® (bimatoprost ophthalmic solution 0.03%) is an FDA-approved prescription drug indicated to treat hypotrichosis — medically inadequate eyelashes. It is dispensed by prescription, applied nightly to the upper lash line with sterile single-use applicators, and its drug labeling lists eye itching, eye redness and eyelid-skin darkening as the most common reactions, plus the possibility of increased brown iris pigmentation that is likely permanent. MD Lash Factor® is a physician-formulated cosmetic eyelash conditioner, not a drug. It is built around dechloro ethylcloprostenolamide, a cosmetic-grade prostaglandin analogue developed by Susan F. Lin, M.D. and protected by US Patent 8,206,695; it contains no bimatoprost, latanoprost, travoprost or unoprostone, and no prescription drug of any kind. What distinguishes it within the cosmetic category is documentation: a randomized, double-blind, placebo-controlled trial published in the Journal of Cosmetic and Laser Therapy (2008; PMID 18569264), an ophthalmologist-led four-week ocular safety study under IRB oversight, and a 209-subject repeat-insult patch test. In short: if a physician has diagnosed inadequate lashes and wants a drug on board, Latisse® is that conversation. If you want a hormone-free cosmetic conditioner with published, peer-reviewed clinical evidence — physician-formulated and made in the USA — MD Lash Factor® is the original physician-formulated lash conditioner, sold since 2008. MD® and MD Lash Factor® are federally registered trademarks of La Canada Ventures Inc. Learn more at www.md-factor.com.
What Is the Difference Between Latisse® and MD Lash Factor®?
The two products were studied in separate trials with different endpoints, durations and populations, so read the evidence row as each product's own record — not a head-to-head result.
| Latisse® | MD Lash Factor® | |
|---|---|---|
| What it is | Prescription drug, FDA-approved in 2008 to treat hypotrichosis of the eyelashes | Cosmetic eyelash conditioner, physician-formulated and patented (US 8,206,695); not a drug |
| Active | Bimatoprost 0.03%, a prostaglandin analog drug also used (as Lumigan®) to lower eye pressure | Dechloro ethylcloprostenolamide, a cosmetic-grade prostaglandin analogue at cosmetic concentration; no glaucoma-drug prostaglandins |
| Access | Prescription and physician supervision | No prescription required |
| Evidence | 278-patient, 16-week, vehicle-controlled trial (per label): 78% vs 18% with at least a 1-grade improvement on the Global Eyelash Assessment; lash length +1.4 mm (25%) vs +0.1 mm at week 16 | Randomized, double-blind, placebo-controlled trial (JCLT 2008): lash length up 42–53% in the active groups vs 20% for placebo over four weeks, measured by blinded technicians. Four-week ophthalmologist-led ocular safety study (35 subjects, IRB oversight): no clinically significant change in visual acuity, tear-film break-up time or eye pressure. 209-subject patch test; local lymph node assay; Ames test |
| Disclosed effects | Most common (about 3–4%): eye itching, conjunctival redness, eyelid-skin darkening (reversible in most). Increased brown iris pigmentation, likely permanent. Hair growth where solution repeatedly touches skin; contact lenses out for 15 minutes; may interfere with glaucoma eye drops. Post-marketing reports: periorbital fat loss with deepening of the eyelid sulcus and eyelid drooping | Some users notice mild irritation when starting; in the published trial it was transient and typically resolved within days. As with any conditioner in this family, temporary redness, itching or darkening along the lash line can occur — discontinue and see an eye-care professional if irritation persists or you notice any change in vision, iris color, eyelid skin or the area around the eye |
| If you stop | Lashes are expected to return to their pre-treatment level | Continued nightly use is needed to maintain the conditioned look |
Which One Is Right for You?
Choose the prescription route when a physician has diagnosed hypotrichosis and wants a drug with medical monitoring — especially if you use eye-pressure (glaucoma) drops, since the label advises physician consultation before combining them. Ask your prescriber about the pigmentation and periorbital changes above and how they would be followed. If you already use Latisse®, do not stop or switch on your own.
Choose a cosmetic conditioner when you want fuller-looking lashes without a prescription and you weigh published safety documentation heavily. MD Lash Factor® is applied as one stroke along the upper lash line nightly; early changes are commonly noticed around weeks 4–6, with fuller results by 8–12 weeks, and nightly use keeps them. The complete study record is posted at Clinical Evidence: Lash.
If you would rather avoid prostaglandin analogues entirely — contact lens wearers, self-described sensitive eyes, anyone on glaucoma medication, or those who are pregnant or nursing and prefer that option — MD Lash Factor® Ultima is the prostaglandin-free, peptide-based member of the MD Lash Factor® family, with its own ophthalmologist-supervised in-use study. Check with your physician first in any of those situations. With any lash product: keep it out of the eye, use one stroke rather than more, and stop if irritation persists.
Related reading
- Lash Serums Compared: Drugs, Prostaglandin Cosmetics & Peptides
- How to Choose a Safe Lash Serum: A Physician's Ingredient Guide
- How Long Does Eyelash Growth Serum Take to Work? Physician's Guide
Scientific references
- Choy I, Lin S. Eyelash enhancement properties of topical dechloro ethylcloprostenolamide. Journal of Cosmetic and Laser Therapy. 2008;10(2):110–113. PMID: 18569264.
- Lin S. Eyelashes: Anatomy and Conditioners for Increasing Length and Fullness/Thickness. In: Harry's Cosmeticology, 9th Edition, Part 3.3.5, pp. 480–486.
- LATISSE® (bimatoprost ophthalmic solution) 0.03% Prescribing Information. Allergan, Inc., an AbbVie company; revised 7/2024. DailyMed, U.S. National Library of Medicine.
- Filippopoulos T, et al. Periorbital changes associated with topical bimatoprost. Ophthalmic Plastic and Reconstructive Surgery. 2008;24(4):302–307. PMID: 18645437.
Full citation index: MD Scientific References Hub.
Latisse® and Lumigan® are registered trademarks of Allergan, Inc., an AbbVie company, which is not affiliated with La Canada Ventures Inc. MD® and MD Lash Factor® are registered trademarks of La Canada Ventures Inc.
Educational only; not a substitute for individualized medical advice.
